Opioid Receptors

Corynantheidine is a mu-opioid receptor (MOR) partial agonist, demonstrating analgesic effects through MOR activation in preclinical models. This compound is primarily utilized in research focused on pain management and the exploration of opioid receptor activity. Its ability to modulate pain responses makes it a valuable tool for studying the mechanisms underlying analgesia and opioid signaling.

Bipiperidinyl 4-ANPP is an opioid compound that interacts primarily with the mu-opioid receptor. This compound demonstrates significant analgesic properties and is utilized in research focused on pain management and opioid receptor pharmacology. Its structural similarity to known opioids positions it as a valuable tool for investigating the mechanisms underlying opioid action and potential therapeutic applications in chronic pain and addiction studies.

Endomorphin 2 is a high-affinity agonist of the μ-opioid receptor, exhibiting selectivity and potency in targeting this pathway. It also shows moderate affinity for kappa3 binding sites, with a Ki value ranging from 20 to 30 nM. This compound is valuable for research in pain management, neurobiology, and the pharmacological characterization of opioid receptors. Its unique properties make it suitable for studies focused on opioid signaling and potential therapeutic applications in pain relief.

AWL 60 is an opioid receptor agonist that also exhibits properties as a substance P (SP) antagonist. This compound has been shown to antagonize SP agonists in vitro, as well as attenuate hypotension induced by SP agonists in vivo. AWL 60 is relevant for research applications focused on pain modulation, opioid receptor signaling, and neuroinflammatory responses.

Pargeverine hydrochloride is an antispasmodic opioid alkaloid that primarily targets muscarinic cholinergic receptors, exhibiting a moderate and non-selective blockade. This compound is utilized in research to investigate mechanisms underlying painful spasms and their management. Its application in understanding muscle contraction and relaxation makes it a valuable reagent in pharmacological studies.

MOR agonist-2 is a potent agonist of the mu-opioid receptor (MOR) with a Ki value of 564 nM, and it acts as an antagonist at the dopamine D3 receptor (D3R) with a Ki of 7.26 nM. This compound exhibits analgesic properties through its partial agonism at MOR, making it a valuable tool for research in pain management. Additionally, its D3R antagonism may help mitigate opioid misuse liability, offering potential therapeutic benefits in addiction studies.